Success Stories: Advancing Biomedical Nanotechnology: EB1A and NIW Petitions Approved Without RFEs
Client’s Testimonial:
“The entire petition process went pretty smoothly. Writing the research materials myself was the most annoying part; it takes a lot of time. But everything else was handled smoothly. My attorney, B., seemed to have a solid understanding of my research, and the petition letter required almost no revisions. Both cases were approved without any RFEs. The process was efficient and professional.”
On October 1st, 2025, and October 18th, 2024, we received I-140 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for a Postdoc Researcher in the Field of Bionanotechnology (Approval Notice).
General Field: Bionanotechnology
Position at the Time of Case Filing: Postdoc Researcher
Country of Origin: China
State of Residence at the Time of Filing: Illinois
Approval Notice Date: October 1st, 2025 (NIW), and October 18th, 2024 (EB1A)
Processing Time: 1 year, 8 months, 19 days (NIW), and 28 days (EB1A, Premium Processing Requested)
Case Summary:
Our client’s pioneering work in bionanotechnology has redefined what is possible in biomedical engineering. Through her research on DNA and RNA nanostructures, she has contributed to new approaches for disease detection, viral intervention, and targeted drug delivery. With the guidance of North America Immigration Law Group (NAILG), she achieved both EB1A and NIW approvals; her EB1A petition was approved in only 28 days under premium processing, and her NIW was approved in just over one year—both without an RFE.
Research with Major Significance:
Her research lies at the intersection of chemistry, biology, and engineering, advancing the design and application of nanoscale materials in healthcare and biotechnology. Her pioneering work on DNA and RNA nanostructures has enabled the creation of stable, programmable biomaterials that are transforming drug delivery systems and diagnostic technologies.
Our client’s studies have addressed key challenges in biomedical engineering, including precise nanostructure assembly, stimuli-responsive design, and biomolecular targeting for therapeutic applications. These innovations are enhancing the efficiency and specificity of treatments while broadening the possibilities for early disease detection. As one expert remarked:
“Through the development of new nanotechnology, [Client]’s work is integral to our nation’s advancement in biomedical engineering, whether through drug applications, viral interventions, or disease identification.”
Academic and Professional Record:
The client’s scientific accomplishments reflect both productivity and influence within her field. Her scholarly record includes:
- 18 peer-reviewed journal articles (4 first-authored and 3 co-first-authored) and 2 book chapters (1 first-authored).
- 453 citations to her published work, demonstrating strong international recognition.
- 18 peer reviews completed for leading journals in nanotechnology and materials science.
- Research funding from major national and international agencies, including the National Science Foundation (NSF), National Institutes of Health (NIH), Office of Naval Research (ONR), Department of Energy (DOE), and the National Natural Science Foundation of China (NSFC).
EB1A and NIW Approvals and Outlook:
By demonstrating original contributions of major significance, sustained recognition, and a proven record of advancing U.S. national interests, our client met the demanding standards of both EB1A and NIW classifications. With both petitions skillfully prepared and filed by North America Immigration Law Group (NAILG), she received swift approvals with no Requests for Evidence.
She will continue her research in the United States, where her ongoing work in DNA- and RNA-based nanostructures will accelerate innovation in biomedical engineering, strengthen national research capacity, and advance public health through cutting-edge nanotechnology.